Humana Inc. (NYSE:HUM) to Post FY2024 Earnings of $16.04 Per Share, Cantor Fitzgerald Forecasts

Humana Inc. (NYSE:HUM) – Research analysts at Cantor Fitzgerald cut their FY2024 EPS estimates for shares of Humana in a note issued to investors on Thursday, April 25th. Cantor Fitzgerald analyst S. James now anticipates that the insurance provider will post earnings per share of $16.04 for the year, down from their prior forecast of $16.07. Cantor Fitzgerald currently has a “Neutral” rating and a $360.00 price objective on the stock. The consensus estimate for Humana’s current full-year earnings is $16.06 per share.

Several other research analysts also recently commented on HUM. Wells Fargo & Company dropped their target price on shares of Humana from $413.00 to $350.00 and set an “overweight” rating on the stock in a report on Monday, April 8th. Mizuho dropped their target price on shares of Humana from $550.00 to $400.00 and set a “buy” rating on the stock in a report on Friday, January 26th. Deutsche Bank Aktiengesellschaft downgraded shares of Humana from a “buy” rating to a “hold” rating and dropped their target price for the stock from $595.00 to $360.00 in a report on Thursday, January 25th. Raymond James started coverage on shares of Humana in a report on Friday, March 22nd. They issued a “market perform” rating on the stock. Finally, Bank of America restated a “neutral” rating and set a $342.00 price objective (down previously from $470.00) on shares of Humana in a report on Tuesday, April 2nd. Eleven equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $433.74.

Humana Stock Performance

Shares of HUM opened at $311.00 on Friday. The company has a market capitalization of $37.52 billion, a PE ratio of 19.39, a price-to-earnings-growth ratio of 1.85 and a beta of 0.45. Humana has a one year low of $299.23 and a one year high of $541.21. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.67 and a quick ratio of 1.59. The company’s fifty day moving average price is $328.56 and its 200 day moving average price is $395.71.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, beating analysts’ consensus estimates of $6.12 by $1.11. The business had revenue of $29.61 billion for the quarter, compared to the consensus estimate of $28.52 billion. Humana had a net margin of 1.82% and a return on equity of 17.76%. Humana’s revenue for the quarter was up 10.7% on a year-over-year basis. During the same quarter last year, the firm earned $9.38 EPS.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.14%. The ex-dividend date of this dividend is Friday, June 28th. Humana’s dividend payout ratio (DPR) is 22.04%.

Insider Buying and Selling

In other Humana news, Director Jorge S. Mesquita purchased 545 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The stock was acquired at an average cost of $367.09 per share, with a total value of $200,064.05. Following the completion of the purchase, the director now directly owns 2,578 shares in the company, valued at approximately $946,358.02. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.32% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Humana

Several large investors have recently bought and sold shares of the company. Rakuten Securities Inc. acquired a new position in shares of Humana in the fourth quarter valued at approximately $25,000. Gradient Investments LLC boosted its holdings in shares of Humana by 200.0% in the fourth quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock valued at $27,000 after buying an additional 40 shares during the period. Cetera Trust Company N.A acquired a new position in shares of Humana in the fourth quarter valued at approximately $28,000. Private Wealth Management Group LLC acquired a new position in shares of Humana in the fourth quarter valued at approximately $32,000. Finally, Nvwm LLC boosted its holdings in shares of Humana by 41.0% in the third quarter. Nvwm LLC now owns 86 shares of the insurance provider’s stock valued at $42,000 after buying an additional 25 shares during the period. Institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.